Piramal Pharma Limited
Momentum (87/100) does the heavy lifting; quality (22/100) is the drag.
Buy zoneSolvency riskPiramal Pharma Limited earns a Sell from StocksWizard, with a blended score of 40/100. At ₹195.61 it trades above our blended DCF and relative-multiples fair value of ₹151.03, about 23% downside to that estimate — we read it as overvalued by 23%. On 39.8x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 6% below its 52-week high of ₹208.28 and 47% above the low of ₹133.27. Financial health scores 29/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 2/9. The average analyst target of ₹203 implies about 4% upside across 11 analysts. It clears 4 of 12 investability checks, with durability 22, valuation 66 and momentum 87 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹120.83.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-6.08% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell40Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: -4.0%
- Fail: Low debt (D/E < 0.5): 0.70x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -0%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: -3.7%
- Pass: Current ratio > 1.5: 1.51
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.14
- Fail: Piotroski ≥ 7: 2/9
Quarterly results
Annual financials
Shareholding
- Promoter54.5%
- Institutions21.4%
- Public & other24.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Low return on equity (-4.0%).
- Weak Piotroski score (2/9).
Threats
- Trades ~23% above our estimated fair value.
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances
Piramal Pharma Limited — frequently asked questions
Is Piramal Pharma Limited a buy, hold or sell?
StocksWizard currently rates Piramal Pharma Limited (PPLPHARMA) a Sell, based on a blended score of 40/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Piramal Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates Piramal Pharma Limited's fair value at about ₹151.03, versus a current price of ₹195.61 — roughly 23% downside. On that basis the stock looks overvalued by 23%.
Is Piramal Pharma Limited financially healthy?
Piramal Pharma Limited scores 29/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has Piramal Pharma Limited's share price performed?
Piramal Pharma Limited is up 22% over three months, and last traded at ₹195.61. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.